Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer
Thyroid cancer is the most common malignant neoplasm within the endocrine system and the field of head and neck surgery. Although the majority of thyroid cancers, more than 90%, are well-differentiated thyroid carcinomas with a favourable prognosis, the escalating incidence of this disease has contributed to an increasing number of patients with a propensity for recurrent disease, rapid disease progression, and poor or no response to conventional treatments. These clinical challenges are commonly attributed to alterations in key thyroid oncogenes or signaling pathways, thereby initiating tumour cell dedifferentiation event...
Source: Frontiers in Endocrinology - January 19, 2024 Category: Endocrinology Source Type: research
Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer
(Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - January 18, 2024 Category: Nuclear Medicine Source Type: research
Retrospective case –control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer
ConclusionsChanges in thyroglobulin levels pre- and post-therapy were associated with RFS. Patients with decreased post-therapy thyroglobulin levels had a favorable prognosis, even if their thyroglobulin levels were positive after RAI therapy. (Source: Japanese Journal of Radiology)
Source: Japanese Journal of Radiology - January 12, 2024 Category: Radiology Source Type: research
Predictive factors for the outcome of radioiodine therapy in patients with benign thyroid diseases
CONCLUSION: Reduction of thyroid volume and the percentage of hypothyroid patients one year after RIT was primarily dependent on the type of disease. In MUFA and DISA we could identify volume reduction after 3 months as a reliable predictor for hypothyroidism while in patients with GD a short intra-therapeutic half-life, a large pre-therapeutic volume and active Graves' ophtalmopathy were relevant predictors for treatment failure suggesting an intensified follow-up scheme in these patients.PMID:38190997 | DOI:10.1055/a-2191-3113 (Source: Nuklearmedizin)
Source: Nuklearmedizin - January 8, 2024 Category: Radiology Authors: Florian Wedel Thomas Exarchopoulos Winfried Brenner Source Type: research
[ < sup > 18 < /sup > F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patients
CONCLUSIONS: In subjects with iodine-negative TC, [18F]FDG PET/CT triggered relevant management changes along with disease control in the vast majority of patients. As such, in dedifferentiated TC, [18F]FDG PET/CT may serve as a relevant management tool and therapeutic decision-aid in the clinic.PMID:38133766 | DOI:10.1007/s12020-023-03645-8 (Source: Cancer Control)
Source: Cancer Control - December 22, 2023 Category: Cancer & Oncology Authors: Yingjun Zhi Takahiro Higuchi Stephan Hackenberg Rudolf Hagen Manuel St öth Agmal Scherzad Andreas K Buck Rudolf A Werner Sebastian E Serfling Source Type: research
[18F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patients
ConclusionsIn subjects with iodine-negative TC, [18F]FDG PET/CT triggered relevant management changes along with disease control in the vast majority of patients. As such, in dedifferentiated TC, [18F]FDG PET/CT may serve as a relevant management tool and therapeutic decision-aid in the clinic. (Source: Endocrine)
Source: Endocrine - December 22, 2023 Category: Endocrinology Source Type: research
Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes
ConclusionsEarly identification of molecular markers in primary tumours may help to predict RAI therapy avidity, the response of metastatic lesions and to select the patients that may benefit the most from other systemic therapies. (Source: Endocrine)
Source: Endocrine - December 16, 2023 Category: Endocrinology Source Type: research
The potential association of peripheral inflammatory biomarkers in patients with papillary thyroid cancer before radioiodine therapy to clinical outcomes
ConclusionWe found that higher PLR values was associated with poor clinicopathological features in PTC. However, the peripheral inflammatory indicators (NLR, LMR and PLR) may be insufficient to predict short-term clinical outcomes of patients with radioiodine therapy. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - December 15, 2023 Category: Endocrinology Source Type: research
Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior VEGFR-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study
CONCLUSIONS: Results indicate that cabozantinib benefits patients with radioiodine-refractory DTC, regardless of prior lenvatinib or sorafenib treatments or histology.PMID:38062732 | DOI:10.1089/thy.2023.0463 (Source: Thyroid : official journal of the American Thyroid Association)
Source: Thyroid : official journal of the American Thyroid Association - December 8, 2023 Category: Endocrinology Authors: Jaume Capdevila Jolanta Krajewska Jorge Hernando Bruce Robinson Steven I Sherman Barbara Jarzab Chia-Chi Lin Fernanda Vaisman Ana Oliveira Hoff Erika Hitre Daniel Bowles Denise Williamson Roman Levytskyy Jennifer W Oliver Bhumsuk Keam Marcia Brose Source Type: research
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
Conclusion: Our data show a significant association between the onset of RR-TC and mutations in telomerase reverse transcriptase promoter and tumor protein 53, indicating the need for a more extensive diagnostic workup in these patients. Certain genetic changes put patients with thyroid cancer at risk of developing cancer spread that does not respond to radioiodine therapy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Laschinsky, C., Theurer, S., Herold, T., Rawitzer, J., Weber, F., Herrmann, K., Brandenburg, T., Fuhrer-Sakel, D., Fendler, W. P., Weber, M. Tags: Brief Communications Source Type: research
Clinical potential of microbiota in thyroid cancer therapy
Biochim Biophys Acta Mol Basis Dis. 2023 Nov 28;1870(2):166971. doi: 10.1016/j.bbadis.2023.166971. Online ahead of print.ABSTRACTThyroid cancer is one of the most common tumors of the endocrine system because of its rapid and steady increase in incidence and prevalence. In recent years, a growing number of studies have identified a key role for the gut, thyroid tissue and oral microbiota in the regulation of metabolism and the immune system. A growing body of evidence has conclusively demonstrated that the microbiota influences tumor formation, prevention, diagnosis, and treatment. We provide extensive information in which...
Source: Biochimica et Biophysica Acta - November 29, 2023 Category: Biochemistry Authors: Zilan Xie Jiating Zhou Xuan Zhang Zhi Li Source Type: research
Family history of malignant or benign thyroid tumors: implications for surgical procedure management and disease-free survival
ConclusionOur findings indicate that a family history, particularly of malignancy, is associated with a more aggressive disease. Family history does not affect the prognosis of patients who undergo total thyroidectomy, but it may increase the risk of postoperative malignant events in those who have a lobectomy. Additionally, it may be necessary to monitor individuals with a family history of benign thyroid neoplasms. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - November 29, 2023 Category: Endocrinology Source Type: research
